FDA Brief

Warning letters Drugs

FDA warning letter to

Ningbo Riway Industrial Co., Ltd.

High riskIssued Apr 30, 2025Posted May 13, 2025Center for Drug Evaluation and Research (CDER)

Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

What happened

FDA reviewed records Ningbo Riway submitted after a March 11, 2024 records request, not an inspection. FDA found Current Good Manufacturing Practice (CGMP) failures: no identity testing of incoming components including isopropyl alcohol for methanol, no adequate finished-product testing including microbiological tests for products labeled sterile, and inadequate quality-unit oversight of the water system and component approvals. FDA also found KLEAN FREAK BODY WIPE and JJ CARE ADHESIVE REMOVER WIPES were unapproved new drugs and misbranded based on their labels; the firm was placed on Import Alert 66-40, which can block U.S. entries, on November 7, 2024.

What FDA found

  1. The firm did not test each incoming component lot for identity and did not verify supplier test results at appropriate intervals; it also did not test isopropyl alcohol for methanol.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm did not adequately test finished drug products before release for active ingredient identity and strength, impurities, and microbiological quality, including for products labeled sterile.

    21 CFR 211.165(a)
  3. The quality unit did not adequately oversee quality, including the water system used for sterile IPA prep pads and approval or rejection of components.

    21 CFR 211.22(a)
  4. KLEAN FREAK BODY WIPE is an unapproved new drug (sold without required FDA approval or OTC rule compliance) and misbranded (illegally labeled) because its label directions extend use beyond the hands allowed for consumer antiseptic rubs.

    FD&C Act sections 505(a), 301(d), and 502(ee); section 505G
  5. JJ CARE ADHESIVE REMOVER WIPES is an unapproved new drug and misbranded because its 1% isopropyl alcohol is below the required concentration for an OTC antiseptic.

    FD&C Act sections 505(a), 301(d), and 502(ee); section 505G and OTC Monograph M003

What FDA wants

FDA tells the firm to correct the violations promptly, engage a qualified CGMP consultant if it intends to resume making drugs for the U.S. market, and respond in writing within 15 working days with corrective actions and a plan to prevent recurrence. If it cannot finish, it must give reasons and a completion schedule.

Who should pay attention

  • brands that buy OTC wipes or prep pads from this contract manufacturer
  • U.S. distributors and importers of antiseptic wipes
  • companies relying on supplier COAs for high-risk ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk